EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSNBRG00000022737
Gene Symbol: CACNA1B
3 Cross references
218 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSNBRG00000001006
Gene Symbol: CACNA1D
4 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSNBRG00000012033
Gene Symbol: CACNA1E
3 Cross references
206 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSNBRG00000016009
Gene Symbol: CACNA1G
3 Cross references
196 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSNBRG00000011849
Gene Symbol: CNR1
2 Cross references
134 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSNBRG00000022564
Gene Symbol: CNR1
1 Cross references
150 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSNBRG00000010586
Gene Symbol: CNR2
1 Cross references
191 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSNBRG00000017306
Gene Symbol: CA12
1 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSNBRG00000016006
Gene Symbol: LOC102786581
3 Cross references
212 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSNBRG00000019363
Gene Symbol: LOC102778747
3 Cross references
194 Possible Orthologues:

Carbonic Anhydrase 5b, Mitochondrial-Like

Ensembl ID : ENSNBRG00000008616
Gene Symbol: LOC102795873
3 Cross references
231 Possible Orthologues:

Carbonic Anhydrase 6

Ensembl ID : ENSNBRG00000007752
Gene Symbol: CA6
3 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).